The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
argenx SE(NASDAQ:ARGX) 
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia...
Website: http://www.argenx.com
Founded: 2008
Full Time Employees: 186
Sector: Healthcare
Industry: Biotechnology
argenx SE Days Payable Outstanding ttm (DPO)
argenx SE Days Receivable Outstanding ttm (DSO)
argenx SE Days Inventory Outstanding ttm (DIO)
argenx SE Op Cashflow Per Share ttm
argenx SE Free Cashflow Per Share ttm
argenx SE Cash Per Share ttm
argenx SE P/S ratio ttm
argenx SE (GAAP) P/E ratio ttm
argenx SE P/B ratio ttm
No extra charts and metrics for this ticker.